삼일제약

000520KOSPI의약품 제조업

38.0 / 100

Reference Date: 2026-07-24

Financial Score7.5 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Slightly up 2.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Samil Pharmaceutical, established in 1947, is a mid-sized pharmaceutical company specializing in ophthalmology, epilepsy, and digestive system drugs, with a business structure focused on original and generic drug development, production, and sales. In 2025, its consolidated sales reached 210.3 billion won, and it has secured domestic sales rights for NASH treatment 'Aramchol' and osteoarthritis treatment 'Lorecivivint', while also completing a global ophthalmology CMO plant in Vietnam.

Number of Employees

614people

Average Salary

67.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

1.07Industry Average 0.812.5Point

Higher than industry avg (caution)

ROE

-22.41Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

39.90Industry Average 12.430.0Point

3.2x industry avg (risky)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼9923.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -8.3% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 6,600Won52-week high 12,31052-week low 5,940

1-month return4.0Point

1m +2.17% (slight rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-21
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-01